BioRestorative Therapies, Inc. Stock Other OTC
Equities
BRTX
US0906554086
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 580K | Sales 2025 * | 1.18M | Capitalization | 12.32M |
---|---|---|---|---|---|
Net income 2024 * | -16M | Net income 2025 * | -21M | EV / Sales 2024 * | 21.2 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 10.4 x |
P/E ratio 2024 * |
-0.88
x | P/E ratio 2025 * |
-0.84
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 73.08% |
Managers | Title | Age | Since |
---|---|---|---|
Lance Alstodt
CEO | Chief Executive Officer | 53 | 18-09-30 |
Robert Kristal
DFI | Director of Finance/CFO | - | 21-11-03 |
Compliance Officer | 55 | 15-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Williams
BRD | Director/Board Member | 51 | 21-10-28 |
David Rosa
BRD | Director/Board Member | 59 | 21-10-28 |
Francisco Silva
CTO | Chief Tech/Sci/R&D Officer | 49 | 11-04-12 |
1st Jan change | Capi. | |
---|---|---|
+20.14% | 127B | |
+25.19% | 117B | |
+25.56% | 27.77B | |
-20.64% | 20.44B | |
-14.36% | 16.62B | |
-13.46% | 15.92B | |
-46.67% | 14.94B | |
+12.68% | 14.74B | |
+56.09% | 14.38B |